Siemens Healthineers stock gets higher targets without rating upgrades

Published on 11/12/2026 at 17:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Siemens Healthineers stock draws higher price targets from Goldman Sachs and Deutsche Bank Research, but both firms keep their ratings unchanged. Profit guidance remains below fiscal 2026 earnings.

Analysts raise targets but stay cautious

Goldman Sachs and Deutsche Bank Research lifted their Siemens Healthineers price targets while keeping Neutral and Hold ratings.
The fiscal 2027 earnings range remains below the result achieved in fiscal 2026.
Diagnostics weakness and the planned carve-out remain central risks for the turnaround.

Siemens Healthineers, DE000SHL1006, Illustration mit AI erstellt.

Siemens Healthineers stock is facing a mixed analyst signal on Thursday, November 12: Goldman Sachs and Deutsche Bank Research have raised their price targets, but neither firm has changed its rating. The development was reported in an Ad Hoc News analysis.

Higher targets, unchanged ratings

Goldman Sachs lifted its target to 49 euros from 43 euros while retaining a Neutral stance. Deutsche Bank Research moved its target to 43 euros from 39 euros and kept a Hold rating. The combination points to improving expectations for the shares without confirming that earnings momentum has become strong enough for a more constructive view.

The main constraint is the profit outlook. Siemens Healthineers guided for adjusted basic earnings per share of 2.20 to 2.40 euros in fiscal 2027, below the 2.42 euros achieved in fiscal 2026. Comparable revenue is expected to grow by 4.0 to 5.0 percent, while the fiscal 2026 adjusted EBIT margin reached 16.2 percent.

Diagnostics remains the test

The company entered the new fiscal year with stronger fourth-quarter momentum. Comparable revenue rose 5.9 percent in the quarter, but Diagnostics contracted 4.2 percent on a comparable basis. Imaging growth and the planned portfolio changes therefore need to offset continued pressure in the diagnostics business.

The analysis also highlights reported cost-saving targets of 400 million euros at Diagnostics and at least 300 million euros in the core business. For investors, those measures become material only if they improve earnings stability rather than merely offset weakness elsewhere in the portfolio.

The planned carve-out is intended to turn the in-vitro diagnostics business into a standalone organization by mid-2028 under the name Olyrian Diagnostics. Siemens Healthineers also plans to shorten its name to Healthineers, with the rebrand expected to begin in 2027 and run over three years.